PharmiWeb.com - Global Pharma News & Resources
14-Feb-2019

Atypical Antipsychotic Drugs Market is poised to touch significant value by 2026 added in new research

Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. Atypical antipsychotic drugs do not cure psychosis but help in controlling symptoms such as hallucinations, paranoia, hearing voices, and delusions, among others. Atypical antipsychotics produce a sedative or tranquilizing effect.

Increasing incidence of psychotic disorders and presence of large patient pool in developed and in some developing economies are major factors driving adoption of antipsychotic drugs and in turn fueling growth of the global atypical antipsychotic drugs market. Additionally, increasing availability of advanced antipsychotic drugs that are used for specialized treatment of certain psychotic disorders is another factor anticipated to boost growth of the global market over the forecast period. However, high associated costs and side effects caused due to use of antipsychotic drugs are major factors hampering growth of the global market.

The global antipsychotic drugs market report has been segmented on the basis of drug generation type, application, and region. On the basis of region, the global antipsychotic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Global atypical antipsychotic drugs market segmentation:

By drug class:

  • Risperidone
  • Olanzapine
  • Quetiapine
  • Ziprasidone
  • Aripiprazole
  • Paliperidone
  • Lurasidone

By indication:

  • Bipolar I Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Major Depressive Disorder (MDD)

By distribution channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Store
  • E-commerce

Get Free Sample Copy Of This Research @ https://marketresearch.biz/report/atypical-antipsychotic-drugs-market/request-sample/

Currently, the market in North America dominates the global atypical antipsychotic drugs market in revenue terms owing to high awareness about psychotic disorders, presence of proper healthcare infrastructure, and easy availability of atypical antipsychotic drugs in countries in the region. The market in Europe accounted for second-highest revenue share in the global atypical antipsychotic drugs market.

Prominent players in the global atypical antipsychotic drugs market include GlaxoSmithKline Plc., Johnson and Johnson, Pfizer Inc., Eil Lilly and Company, Bristol-Myers Squibb Company, Allergan Plc., Cardinal Health Inc., Sanis Health Inc., Ranbaxy Inc. (Sun Pharmaceutical Industries Ltd.), Novartis AG.

Editor Details

Last Updated: 14-Feb-2019